Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the environment on the health: From theory to practice.
Carducci AL, Agodi A, Ancona C, Angelini P, Bagordo F, Barbone F, Birbaum L, Carreri V, Casuccio A, Conti A, Conversano M, De Donno A, De Giglio O, Desiante F, Di Pietro A, Dogliotti E, Donato F, Fara GM, Fiore M, Forastiere F, Giammanco G, Izzotti A, Montagna MT, Oliveri Conti G, Petronio MG, Sciacca S, Signorelli C, Testai E, Verani M, Vinceti M, Vitale F, Ferrante M; Attendees* (in alphabetical order) to the 56th Erice Course “Evaluation of the impact on environment and health: from theory to practice” and Contributors to the discussion and preparations of The Erice 56 Charter.; Adani G, Berghella L, Calia C, Calzolari R, Canale A, Castiglione D, Conti A, Copat C, Cristaldi A, Cuffari G, Coronel Vargas G, De Vita E, De Nard F, Federigi I, Filippini T, Grasso A, Leonardi N, Letzgus M, Lo Bianco G, Mazzucco W, Nicolosi I, Orlandi P, Paladino G, Pizzo S, Pousis C, Raffo M, Rivolta S, Scarpitta F, Trani G, Triggiano F, Tumbarello A, Vecchio V, Zuccarello P, Vassallo M. Carducci AL, et al. Among authors: orlandi p. Environ Res. 2021 Mar;194:110517. doi: 10.1016/j.envres.2020.110517. Epub 2020 Dec 1. Environ Res. 2021. PMID: 33271142
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G. Allegrini G, et al. Among authors: orlandi p. Angiogenesis. 2012 Jun;15(2):275-86. doi: 10.1007/s10456-012-9260-6. Epub 2012 Mar 2. Angiogenesis. 2012. PMID: 22382585 Free PMC article.
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G. Derosa L, et al. Among authors: orlandi p. Cancer. 2014 Dec 15;120(24):3923-31. doi: 10.1002/cncr.28953. Epub 2014 Aug 8. Cancer. 2014. PMID: 25111199 Free article. Clinical Trial.
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
Allegrini G, Coltelli L, Orlandi P, Fontana A, Camerini A, Ferro A, Cazzaniga M, Casadei V, Lucchesi S, Bona E, Di Lieto M, Pazzagli I, Villa F, Amoroso D, Scalese M, Arrighi G, Molinaro S, Fioravanti A, Finale C, Triolo R, Di Desidero T, Donati S, Marcucci L, Goletti O, Del Re M, Salvadori B, Ferrarini I, Danesi R, Falcone A, Bocci G. Allegrini G, et al. Among authors: orlandi p. Pharmacogenomics. 2014 Dec;15(16):1985-99. doi: 10.2217/pgs.14.140. Pharmacogenomics. 2014. PMID: 25521357 Clinical Trial.
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. Ferrari SM, et al. Among authors: orlandi p. Oncol Rep. 2018 May;39(5):2225-2234. doi: 10.3892/or.2018.6306. Epub 2018 Mar 8. Oncol Rep. 2018. PMID: 29517103
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics.
Di Desidero T, Orlandi P, Fioravanti A, Alì G, Cremolini C, Loupakis F, Gentile D, Banchi M, Cucchiara F, Antoniotti C, Masi G, Fontanini G, Falcone A, Bocci G. Di Desidero T, et al. Among authors: orlandi p. Biochem Pharmacol. 2019 Jun;164:94-105. doi: 10.1016/j.bcp.2019.04.001. Epub 2019 Apr 3. Biochem Pharmacol. 2019. PMID: 30953637
242 results